BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines bRUKINSA — United States Revenue Growth YoY (%) (%)
Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases
Latest, FY2025
45.1%
Period ended Dec 31, 2025
Change on a year earlier
-61.2 pts
106.3% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BRUKINSA — United States Revenue Growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 45.1% | -61.2 pts | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 106.3% | -36.3 pts | Form 10-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 142.6% | -94.4 pts | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 237.0% | -298.0 pts | Form 10-K (filed 2023-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 535.0% | – | Form 8-K (filed 2022-02-25) ↗ |
Cite this data
StockData. (2026). BeOne Medicines BRUKINSA — United States Revenue Growth YoY (%) (%), annual FY2021–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_brukinsa_us_yoy
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.